FYERS
Home
/
Stocks
/
Results
/
Cohance Lifesciences Results

Cohance Lifesciences Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-18%19%-13%
--13%-24%-69%
--3%-4%-49%
24%19%12%4%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
COHANCE
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,899₹456833 Cr37.7712.0762.82₹11479 Cr
9,100₹245426 Cr83.9134.04128.41₹2568 Cr
4,857₹187320 Cr85.8916.7297.06₹2163 Cr
1,120₹113217 Cr25.099.4262.53₹5040 Cr
1,385₹112212 Cr33.299.7757.87₹3879 Cr
1,840₹101155 Cr92.526.829.25₹889 Cr
2,110₹97626 Cr17.6630.95154.36₹5333 Cr
2,327.9₹96859 Cr47.4213.7571.08₹1913 Cr
1,151₹96406 Cr29.925.3263.99₹4196 Cr
1,653.1₹93614 Cr25.2217.9596.84₹3505 Cr
456₹17605 Cr165.73-0.637.79₹179 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019
₹422 Cr₹619 Cr₹545 Cr₹556 Cr₹549 Cr₹840 Cr₹676 Cr₹604 Cr₹488 Cr₹253 Cr₹220 Cr₹231 Cr₹348 Cr₹369 Cr₹354 Cr₹278 Cr₹339 Cr₹364 Cr₹392 Cr₹301 Cr₹264 Cr₹259 Cr₹275 Cr₹237 Cr₹238 Cr₹185 Cr₹179 Cr₹273 Cr₹197 Cr₹251 Cr
₹12 Cr-₹2 Cr₹6 Cr₹16 Cr₹14 Cr₹12 Cr₹22 Cr₹16 Cr₹19 Cr₹17 Cr₹14 Cr₹20 Cr₹11 Cr₹11 Cr₹13 Cr₹11 Cr₹11 Cr₹17 Cr₹65 Cr₹5 Cr₹6 Cr₹3 Cr₹5 Cr₹36 L₹6 Cr₹5 Cr₹5 Cr₹5 Cr₹2 Cr₹41 L
₹435 Cr₹617 Cr₹551 Cr₹571 Cr₹563 Cr₹852 Cr₹698 Cr₹620 Cr₹507 Cr₹270 Cr₹234 Cr₹251 Cr₹358 Cr₹381 Cr₹367 Cr₹289 Cr₹350 Cr₹381 Cr₹456 Cr₹306 Cr₹270 Cr₹262 Cr₹280 Cr₹238 Cr₹244 Cr₹190 Cr₹184 Cr₹278 Cr₹200 Cr₹251 Cr
₹471 Cr₹572 Cr₹496 Cr₹479 Cr₹482 Cr₹665 Cr₹482 Cr₹436 Cr₹394 Cr₹197 Cr₹167 Cr₹144 Cr₹192 Cr₹210 Cr₹219 Cr₹191 Cr₹199 Cr₹217 Cr₹216 Cr₹188 Cr₹158 Cr₹174 Cr₹146 Cr₹147 Cr₹134 Cr₹115 Cr₹105 Cr₹153 Cr₹100 Cr₹135 Cr
₹13 Cr₹97 Cr₹102 Cr₹137 Cr₹126 Cr₹241 Cr₹259 Cr₹222 Cr₹145 Cr₹90 Cr₹80 Cr₹118 Cr₹178 Cr₹183 Cr₹160 Cr₹111 Cr₹162 Cr₹174 Cr₹251 Cr₹127 Cr₹120 Cr₹97 Cr₹143 Cr₹98 Cr₹117 Cr₹82 Cr₹84 Cr₹131 Cr₹105 Cr₹122 Cr
₹7 Cr₹9 Cr₹9 Cr₹9 Cr₹10 Cr₹10 Cr₹11 Cr₹10 Cr₹10 Cr₹2 Cr₹2 Cr₹1 Cr₹2 Cr₹5 Cr₹1 Cr₹29 L₹1 Cr₹2 Cr₹74 L₹1 Cr₹2 Cr₹2 Cr₹3 Cr₹3 Cr₹3 Cr₹7 Cr₹8 Cr₹4 Cr₹4 Cr₹2 Cr
-₹43 Cr₹20 Cr₹41 Cr₹84 Cr₹63 Cr₹161 Cr₹205 Cr₹174 Cr₹103 Cr₹71 Cr₹65 Cr₹105 Cr₹164 Cr₹166 Cr₹146 Cr₹98 Cr₹149 Cr₹161 Cr₹239 Cr₹116 Cr₹109 Cr₹87 Cr₹132 Cr₹88 Cr₹108 Cr₹68 Cr₹71 Cr₹121 Cr₹96 Cr₹115 Cr
-₹45 Cr₹8 Cr₹29 Cr₹66 Cr₹46 Cr₹117 Cr₹153 Cr₹138 Cr₹75 Cr₹53 Cr₹47 Cr₹80 Cr₹121 Cr₹124 Cr₹108 Cr₹72 Cr₹108 Cr₹92 Cr₹160 Cr₹80 Cr₹81 Cr₹64 Cr₹98 Cr₹65 Cr₹81 Cr₹53 Cr₹52 Cr₹89 Cr₹75 Cr₹75 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
————————
₹38 Cr₹25 Cr₹25 Cr₹25 Cr₹25 Cr₹25 Cr₹13 Cr₹0
₹18 Cr₹82 Cr₹2 Cr₹0₹0₹0₹0₹13 Cr
₹3855 Cr₹3542 Cr₹2023 Cr₹1710 Cr₹1502 Cr₹1155 Cr₹832 Cr₹578 Cr
₹3855 Cr₹3542 Cr₹2023 Cr₹1710 Cr₹1502 Cr₹1155 Cr₹832 Cr₹578 Cr
₹3911 Cr₹3649 Cr₹2051 Cr₹1735 Cr₹1527 Cr₹1181 Cr₹845 Cr₹590 Cr
₹123 Cr₹144 Cr₹0₹0₹0₹0₹0₹0
₹50 Cr₹130 Cr₹0₹5 Cr₹28 Cr₹36 Cr₹0₹0
₹0₹0₹0₹0₹0₹0₹91 Cr₹0
₹95 Cr₹102 Cr₹65 Cr₹58 Cr₹54 Cr₹31 Cr₹28 Cr₹29 Cr
₹901 Cr₹750 Cr₹21 Cr₹70 L₹46 L₹74 L₹51 L₹0
₹40 L₹26 L₹0₹8 Cr₹9 Cr₹7 Cr₹8 Cr₹6 Cr
₹1047 Cr₹982 Cr₹86 Cr₹72 Cr₹92 Cr₹74 Cr₹128 Cr₹35 Cr
————————
₹285 Cr₹268 Cr₹42 Cr₹70 Cr₹106 Cr₹83 Cr₹71 Cr₹54 Cr
₹223 Cr₹313 Cr₹21 Cr₹20 Cr₹30 Cr₹29 Cr₹28 Cr₹19 Cr
₹74 Cr₹71 Cr₹39 Cr₹65 Cr₹67 Cr₹106 Cr₹94 Cr₹83 Cr
₹64 Cr₹53 Cr₹15 Cr₹149 Cr₹145 Cr₹104 Cr₹127 Cr₹35 Cr
₹646 Cr₹705 Cr₹117 Cr₹303 Cr₹348 Cr₹322 Cr₹320 Cr₹191 Cr
₹5727 Cr₹5480 Cr₹2254 Cr₹2110 Cr₹1967 Cr₹1576 Cr₹1292 Cr₹816 Cr
₹53 Cr₹58 Cr₹18 Cr₹6 Cr₹6 Cr₹6 Cr₹10 Cr₹11 Cr
₹170 Cr₹258 Cr₹39 Cr₹69 Cr₹96 Cr₹141 Cr₹185 Cr₹83 Cr
————————
₹4231 Cr₹3788 Cr₹929 Cr₹876 Cr₹694 Cr₹570 Cr₹457 Cr₹347 Cr
₹862 Cr₹681 Cr₹260 Cr₹212 Cr₹160 Cr₹128 Cr₹100 Cr₹77 Cr
₹3369 Cr₹3107 Cr₹670 Cr₹663 Cr₹534 Cr₹441 Cr₹357 Cr₹271 Cr
₹173 Cr₹332 Cr₹179 Cr₹165 Cr₹30 Cr₹96 Cr₹102 Cr₹111 Cr
₹262 Cr₹145 Cr₹131 Cr₹117 Cr₹117 Cr₹361 Cr₹307 Cr₹7 L
₹262 Cr₹145 Cr₹131 Cr₹117 Cr₹117 Cr₹361 Cr₹307 Cr₹7 L
₹71 Cr₹86 Cr₹22 Cr₹9 Cr₹13 Cr₹11 Cr₹15 Cr₹11 Cr
₹19 Cr₹13 Cr₹0₹0₹7 Cr₹16 L₹20 L₹22 L
₹3899 Cr₹3687 Cr₹1001 Cr₹955 Cr₹702 Cr₹910 Cr₹781 Cr₹393 Cr
————————
₹266 Cr₹192 Cr₹774 Cr₹419 Cr₹481 Cr₹181 Cr₹31 Cr₹7 Cr
₹562 Cr₹467 Cr₹231 Cr₹313 Cr₹283 Cr₹201 Cr₹175 Cr₹157 Cr
₹681 Cr₹772 Cr₹134 Cr₹111 Cr₹236 Cr₹102 Cr₹117 Cr₹148 Cr
₹60 Cr₹102 Cr₹51 Cr₹68 Cr₹47 Cr₹10 Cr₹14 Cr₹13 Cr
₹42 Cr₹33 Cr₹12 Cr₹11 Cr₹11 Cr₹12 Cr₹9 Cr₹13 Cr
₹185 Cr₹192 Cr₹52 Cr₹233 Cr₹206 Cr₹161 Cr₹165 Cr₹85 Cr
₹1796 Cr₹1758 Cr₹1253 Cr₹1155 Cr₹1265 Cr₹667 Cr₹511 Cr₹423 Cr
₹1150 Cr₹1053 Cr₹1136 Cr₹852 Cr₹918 Cr₹345 Cr₹191 Cr₹232 Cr
₹5727 Cr₹5480 Cr₹2254 Cr₹2110 Cr₹1967 Cr₹1576 Cr₹1292 Cr₹816 Cr
₹102₹140₹80₹68₹60₹46₹66₹0
₹102₹140₹80₹68₹60₹46₹33₹0

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
₹207 Cr₹643 Cr₹406 Cr₹560 Cr₹668 Cr₹468 Cr₹405 Cr₹158 Cr
₹208 Cr₹207 Cr₹17 Cr₹37 Cr₹41 Cr₹36 Cr₹35 Cr₹14 Cr
₹21 Cr-₹73 L₹72 Cr₹6 Cr-₹194 Cr-₹12 Cr₹54 Cr-₹88 Cr
₹436 Cr₹849 Cr₹495 Cr₹603 Cr₹514 Cr₹492 Cr₹493 Cr₹83 Cr
₹368 Cr₹673 Cr₹385 Cr₹457 Cr₹330 Cr₹383 Cr₹407 Cr₹50 Cr
-₹255 Cr-₹390 Cr-₹362 Cr-₹195 Cr-₹136 Cr-₹311 Cr-₹413 Cr-₹65 Cr
-₹165 Cr-₹327 Cr-₹40 Cr-₹242 Cr-₹156 Cr-₹76 Cr₹7 Cr₹26 Cr
-₹51 Cr-₹44 Cr-₹18 Cr₹20 Cr₹37 Cr-₹5 Cr₹79 L₹11 Cr
₹97 Cr₹138 Cr₹65 Cr₹45 Cr₹7 Cr₹12 Cr₹11 Cr₹0
₹4 Cr₹2 Cr₹0₹0₹4,000₹3,000₹6,000₹0
₹49 Cr₹97 Cr₹47 Cr₹65 Cr₹45 Cr₹7 Cr₹12 Cr₹11 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)463.30
Volume (₹)5.73 L
High (₹)470.00
Upper Circuit553.00
Low (₹)453.60
Lower Circuit368.70
Prev Close460.85
52W High (₹)1,038.90
Price456.00
52W Low (₹)266.70

Share Market Cap & Key Ratios Overview

M.Cap (₹)17605.20 Cr
Div. Yield (%)0.00
PE Ratio165.73
Debt to Equity0.04
Price to Book2.97
Book Value101.76
EPS (TTM)2.78
Face Value1.00
ROE (%)4.02

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
COHANCENSE
LTP
1W Low
1W High
Market cap (₹)
1899-21 (-1.09%)
1895
1984.80
4,56,833Cr
9100-139 (-1.50%)
9087
9467
2,45,426Cr
4857-193 (-3.82%)
4823
5066
1,87,320Cr
1120-71 (-5.96%)
1120
1187
1,13,217Cr
1385-38.5 (-2.70%)
1375.50
1426.10
1,12,212Cr
1840-98.5 (-5.08%)
1811.70
1949
1,01,155Cr
2110-61.5 (-2.83%)
2100.60
2192
97,626Cr
2327.9-55 (-2.31%)
2317
2419.20
96,859Cr
1151-27 (-2.29%)
1151
1179.90
96,406Cr
1653.1+7.8 (0.47%)
1622.60
1717
93,614Cr
456+6.1 (1.36%)
444
476.50
17,605Cr

Cohance Lifesciences Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹13.41Cr; with other income of ₹12.25Cr, profit before interest and tax came to ₹-₹36.13Cr. Interest expense was ₹6.74Cr; PBT before exceptional items stood at ₹-₹42.87Cr. Cost mix (full year): raw materials ₹699.92Cr; employee cost ₹507.71Cr; depreciation ₹49.54Cr; other expenses ₹421.1Cr. Basis: consolidated annual results.

Cohance Lifesciences Ltd Quaterly Results Key Takeaways

Cohance Lifesciences Ltd reported ₹422.26Cr total income from operations in Jun 2026, softer than ₹619.12Cr in Mar 2026 but higher than ₹549.31Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹13.41Cr; with other income of ₹12.25Cr, profit before interest and tax came to ₹-₹36.13Cr. Interest expense was ₹6.74Cr, taking profit before tax to ₹-₹42.87Cr. After tax of ₹2.32Cr, profit after tax stood at ₹-₹45.19Cr (vs ₹8.31Cr in Mar 2026 and ₹46.4Cr in Jun 2025).